Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evommune (EVMN) Net Cash Flow (2024 - 2025)

Evommune (EVMN) has disclosed Net Cash Flow for 2 consecutive years, with $17.2 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 1012.11% to $17.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $29.0 million for FY2025, 327.23% up from the prior year.
  • Net Cash Flow for Q4 2025 was $17.2 million at Evommune, up from -$1.9 million in the prior quarter.
  • The five-year high for Net Cash Flow was $17.2 million in Q4 2025, with the low at -$1.9 million in Q4 2024.